Global Hemianopsia- Market

Hemianopsia- Comprehensive Study by Type (Bitemporal, Homonymous, Heteronymous, Superior, Inferior, Others), Treatment (Vision Restoration Therapy (VRT), Visual Field Expander Aid, Visual Auditory Training in Virtual Reality (VR) Headset, Scanning Therapy, Others), End User (Hospitals, Clinics, Rehabilitation Centre, Research Institute, Others) Players and Region - Global Market Outlook to 2030

Hemianopsia- Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hemianopsia-
Hemianopsia, sometimes called hemianopia, is partial blindness or loss of sight in half of visual field. It caused by brain damage, stroke, brain tumour, rather than a problem with eyes. Depending on cause, hemianopia may be permanent or temporary. The significant advances in medical technology and rapid innovations in diagnostic tools, such as advanced imaging techniques and visual field-testing methods that can improve accuracy and efficiency in diagnosing hemianopsia, along with the development of neurorehabilitation therapies, including virtual reality, computer-based training, and neurostimulation techniques, enhancing the rehabilitation and management of the condition are the leading factors expected to boost the hemianopsia market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.3%


Hemianopsia is a fragmented market due to the presence of several players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hemianopsia- market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Vycor Medical Inc. (United States), Retrosense Therapeutics (United States), Chadwick Optical (United States), Healio (United States), ZEISS (Germany), F.Hoffman-La Roche (Switzerland), Novartis AG (Switzerland), Aerie Pharmaceuticals (United States), AKzoNobel N.V (Netherland), AbbVie Inc. (United States), EyeTech Digital (United States) and Bayer AG (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are VisionCare Inc. (United States), Biogen Inc. (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Hemianopsia- market by Type (Bitemporal, Homonymous, Heteronymous, Superior, Inferior and Others) and Region.



On the basis of geography, the market of Hemianopsia- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Vision Restoration Therapy (VRT) will boost the Hemianopsia- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Hemianopsia- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Integration of rehabilitation service.

Market Growth Drivers:
Increasing prevalence of hemianopsia. and Increasing demand for innovative treatment in hemianopsia.

Challenges:
Stringent regulatory requirement.

Restraints:
Limited accessibility to specialized care. and High Treatment cost.

Opportunities:
Technological advancement in medical devices, imaging technique, and treatment of hemianopsia. and Expansion in emerging countries.

Market Leaders and their expansionary development strategies
In August 2022, Alcon, the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies, announced the companies has entered into a definitive merger agreement through which Alcon acquired Aerie. This transaction affirms Alcon’s commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to Alcon’s existing commercial expertise, maximizing the value of its diversified portfolio.
In May 2021, Vedere Bio II, Inc., a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death, announced the completion of its USD 77 million Series a financing. The launch of Vedere Bio II represents a milestone moment in work to restore vision to patients with both genetic and non-genetic causes of vision loss, and new and founding investors.


Key Target Audience
Manufacturers Suppliers and Distributors, Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Government Regulatory, Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Bitemporal
  • Homonymous
  • Heteronymous
  • Superior
  • Inferior
  • Others
By Treatment
  • Vision Restoration Therapy (VRT)
  • Visual Field Expander Aid
  • Visual Auditory Training in Virtual Reality (VR) Headset
  • Scanning Therapy
  • Others

By End User
  • Hospitals
  • Clinics
  • Rehabilitation Centre
  • Research Institute
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of hemianopsia.
      • 3.2.2. Increasing demand for innovative treatment in hemianopsia.
    • 3.3. Market Challenges
      • 3.3.1. Stringent regulatory requirement.
    • 3.4. Market Trends
      • 3.4.1. Integration of rehabilitation service.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemianopsia-, by Type, Treatment, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemianopsia- (Value)
      • 5.2.1. Global Hemianopsia- by: Type (Value)
        • 5.2.1.1. Bitemporal
        • 5.2.1.2. Homonymous
        • 5.2.1.3. Heteronymous
        • 5.2.1.4. Superior
        • 5.2.1.5. Inferior
        • 5.2.1.6. Others
      • 5.2.2. Global Hemianopsia- by: Treatment (Value)
        • 5.2.2.1. Vision Restoration Therapy (VRT)
        • 5.2.2.2. Visual Field Expander Aid
        • 5.2.2.3. Visual Auditory Training in Virtual Reality (VR) Headset
        • 5.2.2.4. Scanning Therapy
        • 5.2.2.5. Others
      • 5.2.3. Global Hemianopsia- by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Rehabilitation Centre
        • 5.2.3.4. Research Institute
        • 5.2.3.5. Others
      • 5.2.4. Global Hemianopsia- Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Hemianopsia-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Vycor Medical Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Retrosense Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Chadwick Optical (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Healio (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ZEISS (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F.Hoffman-La Roche (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aerie Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AKzoNobel N.V (Netherland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. EyeTech Digital (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bayer AG (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Hemianopsia- Sale, by Type, Treatment, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemianopsia- (Value)
      • 7.2.1. Global Hemianopsia- by: Type (Value)
        • 7.2.1.1. Bitemporal
        • 7.2.1.2. Homonymous
        • 7.2.1.3. Heteronymous
        • 7.2.1.4. Superior
        • 7.2.1.5. Inferior
        • 7.2.1.6. Others
      • 7.2.2. Global Hemianopsia- by: Treatment (Value)
        • 7.2.2.1. Vision Restoration Therapy (VRT)
        • 7.2.2.2. Visual Field Expander Aid
        • 7.2.2.3. Visual Auditory Training in Virtual Reality (VR) Headset
        • 7.2.2.4. Scanning Therapy
        • 7.2.2.5. Others
      • 7.2.3. Global Hemianopsia- by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Rehabilitation Centre
        • 7.2.3.4. Research Institute
        • 7.2.3.5. Others
      • 7.2.4. Global Hemianopsia- Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemianopsia-: by Type(USD Million)
  • Table 2. Hemianopsia- Bitemporal , by Region USD Million (2018-2023)
  • Table 3. Hemianopsia- Homonymous , by Region USD Million (2018-2023)
  • Table 4. Hemianopsia- Heteronymous , by Region USD Million (2018-2023)
  • Table 5. Hemianopsia- Superior , by Region USD Million (2018-2023)
  • Table 6. Hemianopsia- Inferior , by Region USD Million (2018-2023)
  • Table 7. Hemianopsia- Others , by Region USD Million (2018-2023)
  • Table 8. Hemianopsia-: by Treatment(USD Million)
  • Table 9. Hemianopsia- Vision Restoration Therapy (VRT) , by Region USD Million (2018-2023)
  • Table 10. Hemianopsia- Visual Field Expander Aid , by Region USD Million (2018-2023)
  • Table 11. Hemianopsia- Visual Auditory Training in Virtual Reality (VR) Headset , by Region USD Million (2018-2023)
  • Table 12. Hemianopsia- Scanning Therapy , by Region USD Million (2018-2023)
  • Table 13. Hemianopsia- Others , by Region USD Million (2018-2023)
  • Table 14. Hemianopsia-: by End User(USD Million)
  • Table 15. Hemianopsia- Hospitals , by Region USD Million (2018-2023)
  • Table 16. Hemianopsia- Clinics , by Region USD Million (2018-2023)
  • Table 17. Hemianopsia- Rehabilitation Centre , by Region USD Million (2018-2023)
  • Table 18. Hemianopsia- Research Institute , by Region USD Million (2018-2023)
  • Table 19. Hemianopsia- Others , by Region USD Million (2018-2023)
  • Table 20. South America Hemianopsia-, by Country USD Million (2018-2023)
  • Table 21. South America Hemianopsia-, by Type USD Million (2018-2023)
  • Table 22. South America Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 23. South America Hemianopsia-, by End User USD Million (2018-2023)
  • Table 24. Brazil Hemianopsia-, by Type USD Million (2018-2023)
  • Table 25. Brazil Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 26. Brazil Hemianopsia-, by End User USD Million (2018-2023)
  • Table 27. Argentina Hemianopsia-, by Type USD Million (2018-2023)
  • Table 28. Argentina Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 29. Argentina Hemianopsia-, by End User USD Million (2018-2023)
  • Table 30. Rest of South America Hemianopsia-, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 32. Rest of South America Hemianopsia-, by End User USD Million (2018-2023)
  • Table 33. Asia Pacific Hemianopsia-, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Hemianopsia-, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 36. Asia Pacific Hemianopsia-, by End User USD Million (2018-2023)
  • Table 37. China Hemianopsia-, by Type USD Million (2018-2023)
  • Table 38. China Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 39. China Hemianopsia-, by End User USD Million (2018-2023)
  • Table 40. Japan Hemianopsia-, by Type USD Million (2018-2023)
  • Table 41. Japan Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 42. Japan Hemianopsia-, by End User USD Million (2018-2023)
  • Table 43. India Hemianopsia-, by Type USD Million (2018-2023)
  • Table 44. India Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 45. India Hemianopsia-, by End User USD Million (2018-2023)
  • Table 46. South Korea Hemianopsia-, by Type USD Million (2018-2023)
  • Table 47. South Korea Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 48. South Korea Hemianopsia-, by End User USD Million (2018-2023)
  • Table 49. Taiwan Hemianopsia-, by Type USD Million (2018-2023)
  • Table 50. Taiwan Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 51. Taiwan Hemianopsia-, by End User USD Million (2018-2023)
  • Table 52. Australia Hemianopsia-, by Type USD Million (2018-2023)
  • Table 53. Australia Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 54. Australia Hemianopsia-, by End User USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Hemianopsia-, by Type USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Hemianopsia-, by End User USD Million (2018-2023)
  • Table 58. Europe Hemianopsia-, by Country USD Million (2018-2023)
  • Table 59. Europe Hemianopsia-, by Type USD Million (2018-2023)
  • Table 60. Europe Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 61. Europe Hemianopsia-, by End User USD Million (2018-2023)
  • Table 62. Germany Hemianopsia-, by Type USD Million (2018-2023)
  • Table 63. Germany Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 64. Germany Hemianopsia-, by End User USD Million (2018-2023)
  • Table 65. France Hemianopsia-, by Type USD Million (2018-2023)
  • Table 66. France Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 67. France Hemianopsia-, by End User USD Million (2018-2023)
  • Table 68. Italy Hemianopsia-, by Type USD Million (2018-2023)
  • Table 69. Italy Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 70. Italy Hemianopsia-, by End User USD Million (2018-2023)
  • Table 71. United Kingdom Hemianopsia-, by Type USD Million (2018-2023)
  • Table 72. United Kingdom Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 73. United Kingdom Hemianopsia-, by End User USD Million (2018-2023)
  • Table 74. Netherlands Hemianopsia-, by Type USD Million (2018-2023)
  • Table 75. Netherlands Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 76. Netherlands Hemianopsia-, by End User USD Million (2018-2023)
  • Table 77. Rest of Europe Hemianopsia-, by Type USD Million (2018-2023)
  • Table 78. Rest of Europe Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 79. Rest of Europe Hemianopsia-, by End User USD Million (2018-2023)
  • Table 80. MEA Hemianopsia-, by Country USD Million (2018-2023)
  • Table 81. MEA Hemianopsia-, by Type USD Million (2018-2023)
  • Table 82. MEA Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 83. MEA Hemianopsia-, by End User USD Million (2018-2023)
  • Table 84. Middle East Hemianopsia-, by Type USD Million (2018-2023)
  • Table 85. Middle East Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 86. Middle East Hemianopsia-, by End User USD Million (2018-2023)
  • Table 87. Africa Hemianopsia-, by Type USD Million (2018-2023)
  • Table 88. Africa Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 89. Africa Hemianopsia-, by End User USD Million (2018-2023)
  • Table 90. North America Hemianopsia-, by Country USD Million (2018-2023)
  • Table 91. North America Hemianopsia-, by Type USD Million (2018-2023)
  • Table 92. North America Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 93. North America Hemianopsia-, by End User USD Million (2018-2023)
  • Table 94. United States Hemianopsia-, by Type USD Million (2018-2023)
  • Table 95. United States Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 96. United States Hemianopsia-, by End User USD Million (2018-2023)
  • Table 97. Canada Hemianopsia-, by Type USD Million (2018-2023)
  • Table 98. Canada Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 99. Canada Hemianopsia-, by End User USD Million (2018-2023)
  • Table 100. Mexico Hemianopsia-, by Type USD Million (2018-2023)
  • Table 101. Mexico Hemianopsia-, by Treatment USD Million (2018-2023)
  • Table 102. Mexico Hemianopsia-, by End User USD Million (2018-2023)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Hemianopsia-: by Type(USD Million)
  • Table 116. Hemianopsia- Bitemporal , by Region USD Million (2025-2030)
  • Table 117. Hemianopsia- Homonymous , by Region USD Million (2025-2030)
  • Table 118. Hemianopsia- Heteronymous , by Region USD Million (2025-2030)
  • Table 119. Hemianopsia- Superior , by Region USD Million (2025-2030)
  • Table 120. Hemianopsia- Inferior , by Region USD Million (2025-2030)
  • Table 121. Hemianopsia- Others , by Region USD Million (2025-2030)
  • Table 122. Hemianopsia-: by Treatment(USD Million)
  • Table 123. Hemianopsia- Vision Restoration Therapy (VRT) , by Region USD Million (2025-2030)
  • Table 124. Hemianopsia- Visual Field Expander Aid , by Region USD Million (2025-2030)
  • Table 125. Hemianopsia- Visual Auditory Training in Virtual Reality (VR) Headset , by Region USD Million (2025-2030)
  • Table 126. Hemianopsia- Scanning Therapy , by Region USD Million (2025-2030)
  • Table 127. Hemianopsia- Others , by Region USD Million (2025-2030)
  • Table 128. Hemianopsia-: by End User(USD Million)
  • Table 129. Hemianopsia- Hospitals , by Region USD Million (2025-2030)
  • Table 130. Hemianopsia- Clinics , by Region USD Million (2025-2030)
  • Table 131. Hemianopsia- Rehabilitation Centre , by Region USD Million (2025-2030)
  • Table 132. Hemianopsia- Research Institute , by Region USD Million (2025-2030)
  • Table 133. Hemianopsia- Others , by Region USD Million (2025-2030)
  • Table 134. South America Hemianopsia-, by Country USD Million (2025-2030)
  • Table 135. South America Hemianopsia-, by Type USD Million (2025-2030)
  • Table 136. South America Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 137. South America Hemianopsia-, by End User USD Million (2025-2030)
  • Table 138. Brazil Hemianopsia-, by Type USD Million (2025-2030)
  • Table 139. Brazil Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 140. Brazil Hemianopsia-, by End User USD Million (2025-2030)
  • Table 141. Argentina Hemianopsia-, by Type USD Million (2025-2030)
  • Table 142. Argentina Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 143. Argentina Hemianopsia-, by End User USD Million (2025-2030)
  • Table 144. Rest of South America Hemianopsia-, by Type USD Million (2025-2030)
  • Table 145. Rest of South America Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 146. Rest of South America Hemianopsia-, by End User USD Million (2025-2030)
  • Table 147. Asia Pacific Hemianopsia-, by Country USD Million (2025-2030)
  • Table 148. Asia Pacific Hemianopsia-, by Type USD Million (2025-2030)
  • Table 149. Asia Pacific Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 150. Asia Pacific Hemianopsia-, by End User USD Million (2025-2030)
  • Table 151. China Hemianopsia-, by Type USD Million (2025-2030)
  • Table 152. China Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 153. China Hemianopsia-, by End User USD Million (2025-2030)
  • Table 154. Japan Hemianopsia-, by Type USD Million (2025-2030)
  • Table 155. Japan Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 156. Japan Hemianopsia-, by End User USD Million (2025-2030)
  • Table 157. India Hemianopsia-, by Type USD Million (2025-2030)
  • Table 158. India Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 159. India Hemianopsia-, by End User USD Million (2025-2030)
  • Table 160. South Korea Hemianopsia-, by Type USD Million (2025-2030)
  • Table 161. South Korea Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 162. South Korea Hemianopsia-, by End User USD Million (2025-2030)
  • Table 163. Taiwan Hemianopsia-, by Type USD Million (2025-2030)
  • Table 164. Taiwan Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 165. Taiwan Hemianopsia-, by End User USD Million (2025-2030)
  • Table 166. Australia Hemianopsia-, by Type USD Million (2025-2030)
  • Table 167. Australia Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 168. Australia Hemianopsia-, by End User USD Million (2025-2030)
  • Table 169. Rest of Asia-Pacific Hemianopsia-, by Type USD Million (2025-2030)
  • Table 170. Rest of Asia-Pacific Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Hemianopsia-, by End User USD Million (2025-2030)
  • Table 172. Europe Hemianopsia-, by Country USD Million (2025-2030)
  • Table 173. Europe Hemianopsia-, by Type USD Million (2025-2030)
  • Table 174. Europe Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 175. Europe Hemianopsia-, by End User USD Million (2025-2030)
  • Table 176. Germany Hemianopsia-, by Type USD Million (2025-2030)
  • Table 177. Germany Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 178. Germany Hemianopsia-, by End User USD Million (2025-2030)
  • Table 179. France Hemianopsia-, by Type USD Million (2025-2030)
  • Table 180. France Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 181. France Hemianopsia-, by End User USD Million (2025-2030)
  • Table 182. Italy Hemianopsia-, by Type USD Million (2025-2030)
  • Table 183. Italy Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 184. Italy Hemianopsia-, by End User USD Million (2025-2030)
  • Table 185. United Kingdom Hemianopsia-, by Type USD Million (2025-2030)
  • Table 186. United Kingdom Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 187. United Kingdom Hemianopsia-, by End User USD Million (2025-2030)
  • Table 188. Netherlands Hemianopsia-, by Type USD Million (2025-2030)
  • Table 189. Netherlands Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 190. Netherlands Hemianopsia-, by End User USD Million (2025-2030)
  • Table 191. Rest of Europe Hemianopsia-, by Type USD Million (2025-2030)
  • Table 192. Rest of Europe Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 193. Rest of Europe Hemianopsia-, by End User USD Million (2025-2030)
  • Table 194. MEA Hemianopsia-, by Country USD Million (2025-2030)
  • Table 195. MEA Hemianopsia-, by Type USD Million (2025-2030)
  • Table 196. MEA Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 197. MEA Hemianopsia-, by End User USD Million (2025-2030)
  • Table 198. Middle East Hemianopsia-, by Type USD Million (2025-2030)
  • Table 199. Middle East Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 200. Middle East Hemianopsia-, by End User USD Million (2025-2030)
  • Table 201. Africa Hemianopsia-, by Type USD Million (2025-2030)
  • Table 202. Africa Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 203. Africa Hemianopsia-, by End User USD Million (2025-2030)
  • Table 204. North America Hemianopsia-, by Country USD Million (2025-2030)
  • Table 205. North America Hemianopsia-, by Type USD Million (2025-2030)
  • Table 206. North America Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 207. North America Hemianopsia-, by End User USD Million (2025-2030)
  • Table 208. United States Hemianopsia-, by Type USD Million (2025-2030)
  • Table 209. United States Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 210. United States Hemianopsia-, by End User USD Million (2025-2030)
  • Table 211. Canada Hemianopsia-, by Type USD Million (2025-2030)
  • Table 212. Canada Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 213. Canada Hemianopsia-, by End User USD Million (2025-2030)
  • Table 214. Mexico Hemianopsia-, by Type USD Million (2025-2030)
  • Table 215. Mexico Hemianopsia-, by Treatment USD Million (2025-2030)
  • Table 216. Mexico Hemianopsia-, by End User USD Million (2025-2030)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemianopsia-: by Type USD Million (2018-2023)
  • Figure 5. Global Hemianopsia-: by Treatment USD Million (2018-2023)
  • Figure 6. Global Hemianopsia-: by End User USD Million (2018-2023)
  • Figure 7. South America Hemianopsia- Share (%), by Country
  • Figure 8. Asia Pacific Hemianopsia- Share (%), by Country
  • Figure 9. Europe Hemianopsia- Share (%), by Country
  • Figure 10. MEA Hemianopsia- Share (%), by Country
  • Figure 11. North America Hemianopsia- Share (%), by Country
  • Figure 12. Global Hemianopsia- share by Players 2023 (%)
  • Figure 13. Global Hemianopsia- share by Players (Top 3) 2023(%)
  • Figure 14. Global Hemianopsia- share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Vycor Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Vycor Medical Inc. (United States) Revenue: by Geography 2023
  • Figure 18. Retrosense Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Retrosense Therapeutics (United States) Revenue: by Geography 2023
  • Figure 20. Chadwick Optical (United States) Revenue, Net Income and Gross profit
  • Figure 21. Chadwick Optical (United States) Revenue: by Geography 2023
  • Figure 22. Healio (United States) Revenue, Net Income and Gross profit
  • Figure 23. Healio (United States) Revenue: by Geography 2023
  • Figure 24. ZEISS (Germany) Revenue, Net Income and Gross profit
  • Figure 25. ZEISS (Germany) Revenue: by Geography 2023
  • Figure 26. F.Hoffman-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. F.Hoffman-La Roche (Switzerland) Revenue: by Geography 2023
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Aerie Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Aerie Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 32. AKzoNobel N.V (Netherland) Revenue, Net Income and Gross profit
  • Figure 33. AKzoNobel N.V (Netherland) Revenue: by Geography 2023
  • Figure 34. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 36. EyeTech Digital (United States) Revenue, Net Income and Gross profit
  • Figure 37. EyeTech Digital (United States) Revenue: by Geography 2023
  • Figure 38. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 40. Global Hemianopsia-: by Type USD Million (2025-2030)
  • Figure 41. Global Hemianopsia-: by Treatment USD Million (2025-2030)
  • Figure 42. Global Hemianopsia-: by End User USD Million (2025-2030)
  • Figure 43. South America Hemianopsia- Share (%), by Country
  • Figure 44. Asia Pacific Hemianopsia- Share (%), by Country
  • Figure 45. Europe Hemianopsia- Share (%), by Country
  • Figure 46. MEA Hemianopsia- Share (%), by Country
  • Figure 47. North America Hemianopsia- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Vycor Medical Inc. (United States)
  • Retrosense Therapeutics (United States)
  • Chadwick Optical (United States)
  • Healio (United States)
  • ZEISS (Germany)
  • F.Hoffman-La Roche (Switzerland)
  • Novartis AG (Switzerland)
  • Aerie Pharmaceuticals (United States)
  • AKzoNobel N.V (Netherland)
  • AbbVie Inc. (United States)
  • EyeTech Digital (United States)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
VisionCare Inc. (United States) , Biogen Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Feb 2024 226 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemianopsia- Market Quantitative research analysis
Global Hemianopsia- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Vycor Medical Inc. (United States), Retrosense Therapeutics (United States), Chadwick Optical (United States), Healio (United States), ZEISS (Germany), F.Hoffman-La Roche (Switzerland), Novartis AG (Switzerland), Aerie Pharmaceuticals (United States), AKzoNobel N.V (Netherland), AbbVie Inc. (United States), EyeTech Digital (United States) and Bayer AG (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Integration of rehabilitation service." is seen as one of major influencing trends for Hemianopsia- Market during projected period 2023-2030.
The Hemianopsia- market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hemianopsia- Market Report?

Have a Query? Click Here

Other Related Reports

Allergic Rhinitis- Comprehensive Study by Type (Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis, Occupational Allergic Rhinitis), Treatment (Immunotherapy, Antihistamines, Decongestant, Corti...
$ 3800
Anophthalmia and Microphthalmia Comprehensive Study by Application (Hospitals, Speciality Clinics, Research Center, Others), Treatment (Surgical Interventions, Prosthetic Devices, Gene Therapy, Pharm...
$ 3800
Thyroid Disorder Therapy Comprehensive Study by Drug Type (Kinase Inhibitors, Anthracyclines, Beta-Blockers, Others), Disease Type (Hypothyroidism, Hyperthyroidism, Goiter, Hashimoto Disease, Others)...
$ 3800
Depression Therapeutics- Comprehensive Study by Indication Type (Major depressive disorder (MDD), Bipolar disorder, Dysthymic disorder, Postpartum depression, Seasonal affective disorder (SAD), Preme...
$ 3800
Ischemic stroke Comprehensive Study by Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, Others), Treatment Type (Tissue Plasminogen Activator, Anticoagulant, A...
$ 3800
Cardiovascular Application Comprehensive Study by Type (Diagnostic and Monitoring Devices, (Electrocardiogram, Holter Monitors, Event Monitors, Others), Interventional Devices, (Coronary Stents, Cath...
$ 3800